UroGen Pharma Ltd. (URGN) Market Cap & Valuation Ratios
UroGen Pharma Ltd. (URGN) has a market cap of $1.7B and a price-to-sales ratio of 8.9, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
URGNUroGen Pharma Ltd.Follow URGN — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| URGN | 1.7 | — | 9.4 | — | -9.4% | +100% | -35% | — |
| PVLA | 1.8 | — | — | — | — | — | — | -199% |
| TRVI | 1.8 | — | — | — | -2.9% | — | — | -34% |
| VIR | 1.8 | — | 4.2 | — | -11.4% | +1496% | -92% | -39% |
| ZBIO | 1.8 | — | — | — | -12.9% | -93% | — | -137% |
| MAZE | 1.7 | — | — | — | -6.2% | — | — | -50% |
| KLRA | 1.7 | — | — | — | — | — | — | — |
| STOK | 1.6 | — | 48.0 | — | -11.2% | -86% | — | -95% |
| NUVB | 1.6 | — | 7.0 | — | -8.0% | +1084% | -81% | -65% |
| NVAX | 1.6 | — | 2.8 | — | -2.7% | -62% | -57% | — |
| IMCR | 1.6 | — | 2.6 | — | -2.6% | +21% | -5% | -7% |
| Median of these 10 | — | 4.2 | — | -7.1% | -20% | -69% | -58% |
; EV/Sales 9.4 vs. 4.2.
Growth vs. price
each dot a company · hover or tap for valuesUroGen Pharma Ltd. — questions
- What is UroGen Pharma Ltd.'s market cap?
- $1.7B.
- What is UroGen Pharma Ltd.'s price-to-sales ratio?
- 8.9.
Every figure on this page comes from UroGen Pharma Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.